Sector Expert: Mick Cooper

Edison Investment Research



Recent Quotes

"Commercial launch of AMBS' LymPro remains on track for H2/14."

— Mick Cooper, Edison Investment Research (8/18/14)
more >

"A good price point for OMER's Omidria at launch and EU approval would maintain momentum through 2014."

— Mick Cooper, Edison Investment Research (7/3/14)
more >

"AMBS has a transformative year ahead and a diverse pipeline of promising products."

— Mick Cooper, Edison Investment Research (5/14/14)
more >



Due to permission requirements, not all quotes are shown.